Just over a week ago Rubicon announced a clinical supply agreement to provide Agendia with its TransPLEX whole genome RNA amplification technology. Agendia will incorporate Rubicon’s TransPLEX kits into the analysis of FFPE patient samples for use with its Symphony™ suite of breast cancer diagnostics. “Velesco provides us an immediate pathway to cGMP kits for diagnostic use and it has the capacity to rapidly expand cGMP production as sales of our diagnostic kits ramp up,” comments James Koziarz, Rubicon CEO.

RNA or DNA extracted from FFPE samples often contains only small amounts of usable DNA or RNA. Rubicon’s TransPLEX genomic RNA amplification kits and GenomePLEX® genomic DNA amplification kits are designed to overcome this issue by delivering sufficient quantities of nucleic acids to enable accurate and consistent analyses.

The TransPLEX and GenomePLEX® kits for fixed and other degraded samples, are part of Rubicon’s OmniPLEX® family of preanalytical products for amplifying and standardizing nucleic acids. The product range includes the PicoPlex WGA kit for whole genome amplification (WGA) from single cells. Rubicon is also developing additional kits for the amplification of nucleic acids from different sample types, including PlasmaPlex™ WGA for use with plasma, serum, and urine, IP-Plex™ WGA for immunoprecipitates, and BC-Plex™ WGA for Bisulfite-converted DNA.

Rubicon offers custom OmniPlex pre-analytical services on a fee-for-service or partnership basis. Services include the PicoPlex NGS for preparing single cells for sequencing on Illumina or GA or HiSeq, MethylPlex WMA for profiling methylation of single cells, plasma, and tissue, PicoPlex WGA, Genome Plex WGA and WTA for FFPE sections, PleasmaPlex WGA, and ChIP-lex WGA for sonicated DNA.

Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.

GEN Poll

Secure Science

Should bans on science education, of the sort imposed on Iranians hoping to study physics and engineering in the United States, encompass other nationals and other fields of study, including biotechnology?

No. Such bans could easily get out of control, preventing the sharing and growth of knowledge.

Yes. The potential, for example, for the development of bioweapons if biotech information gets into the wrong hands must be minimized.

No. Such bans could easily get out of control, preventing the sharing and growth of knowledge.

57.3%

Yes. The potential, for example, for the development of bioweapons if biotech information gets into the wrong hands must be minimized.

If you have any questions about your subscription, click
hereto email us or call at (914) 740-2189.

You may also be interested in subscribing to the GEN magazine, an indispensable
resource for everyone involved in the business of translating discoveries at the
bench into solutions that fight disease and improve health, agriculture, and the
environment. Subscribe
today to see why over 60,000 biotech professionals read GEN to
keep current in the areas of genomics, proteomics, drug discovery, biomarker discovery,
bioprocessing, molecular diagnostics, collaborations, biotech business trends, and
more.